Log In
BCIQ
Print this Print this
 

Vesimune (TMX-101)

  Manage Alerts
Collapse Summary General Information
Company UroGen Pharma Ltd.
DescriptionToll-like receptor 7 (TLR7) agonist
Molecular Target Toll-like receptor 7 (TLR7)
Mechanism of ActionToll-like receptor 7 (TLR7) agonist
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationBladder cancer
Indication DetailsTreat carcinoma in situ (CIS) of the bladder; Treat non-muscle invasive bladder cancer
Regulatory Designation U.S. - Orphan Drug (Treat carcinoma in situ (CIS) of the bladder)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today